Shares of Second Sight Medical Products Inc. (NASDAQ:EYES) were up 6.6% on Friday . The stock traded as high as $4.47 and last traded at $4.34, with a volume of 744,948 shares. The stock had previously closed at $4.07.

Separately, Zacks Investment Research upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Wednesday, June 1st.

The firm’s market capitalization is $149.55 million. The firm has a 50 day moving average of $3.85 and a 200 day moving average of $4.50.

Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings results on Thursday, April 28th. The medical device company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.03. The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.38 million. During the same quarter last year, the firm posted ($0.12) EPS. The business’s revenue for the quarter was down 38.2% compared to the same quarter last year. On average, equities analysts expect that Second Sight Medical Products Inc. will post ($0.65) earnings per share for the current fiscal year.

In other news, Chairman Robert J. Greenberg sold 8,571 shares of the company’s stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total value of $35,141.10. Following the completion of the sale, the chairman now owns 172,911 shares in the company, valued at approximately $708,935.10. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

A hedge fund recently bought a new stake in Second Sight Medical Products stock. Zeke Capital Advisors LLC bought a new stake in Second Sight Medical Products Inc. (NASDAQ:EYES) during the fourth quarter, according to its most recent filing with the SEC. The institutional investor bought 496,428 shares of the medical device company’s stock, valued at approximately $2,924,000. Second Sight Medical Products accounts for 2.5% of Zeke Capital Advisors LLC’s portfolio, making the stock its 10th largest position. Zeke Capital Advisors LLC owned 1.38% of Second Sight Medical Products as of its most recent filing with the SEC.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.